The estimated Net Worth of Michael P. Samar is at least 1.35 百万$ dollars as of 25 July 2022. Mr Samar owns over 2,020 units of Assembly Biosciences Inc stock worth over 1,342,223$ and over the last 5 years he sold ASMB stock worth over 9,443$.
Sign up
Mr Samar ASMB stock SEC Form 4 insiders trading
Mr has made over 2 trades of the Assembly Biosciences Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 2,020 units of ASMB stock worth 4,484$ on 25 July 2022.
The largest trade he's ever made was selling 2,285 units of Assembly Biosciences Inc stock on 29 March 2022 worth over 4,958$. On average, Mr trades about 538 units every 15 days since 2019. As of 25 July 2022 he still owns at least 77,228 units of Assembly Biosciences Inc stock.
You can see the complete history of Mr Samar stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Michael P. Samar biography
Michael P. Samar is the CFO & Principal Accounting Officer at Assembly Biosciences Inc.
How old is Mr Samar?
Mr Samar is 49, he's been the CFO & Principal Accounting Officer of Assembly Biosciences Inc since . There are 12 older and 5 younger executives at Assembly Biosciences Inc. The oldest executive at Assembly Biosciences Inc is Alan Lewis, 74, who is the Independent Director.
What's Mr Samar's mailing address?
Michael's mailing address filed with the SEC is C/O UNITY BIOTECHNOLOGY, INC., 285 EAST GRAND AVENUE, SOUTH SAN FRANCSICO, CA, 94080.
Insiders trading at Assembly Biosciences Inc
Over the last 10 years, insiders at Assembly Biosciences Inc have traded over 1,523,622$ worth of Assembly Biosciences Inc stock and bought 1,245,980 units worth 1,060,065$ . The most active insiders traders include Sciences, Inc. Gilead、Myron Z Holubiak、Helen Susan Kim. On average, Assembly Biosciences Inc executives and independent directors trade stock every 46 days with the average trade being worth of 389,399$. The most recent stock trade was executed by Nicole S White on 2 August 2024, trading 785 units of ASMB stock currently worth 11,171$.
What does Assembly Biosciences Inc do?
assembly biosciences, inc. (nasdaq: asmb) is a public clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis b virus (hbv) infection and novel oral live biotherapeutics for disorders associated with the microbiome. assembly is developing two innovative platform programs: an hbv program advancing a new class of oral therapeutics for the treatment of hepatitis b virus (hbv) infection and a microbiome program developing novel oral live biotherapeutics designed to address diseases associated with the microbiome. assembly’s hbv program is advancing multiple drug candidates with the aim of increasing cure rates in patients with chronic hbv. the company's microbiome program consists of a fully integrated platform that includes a robust strain identification and selection process, methods for strain isolation and growth under current good manufacturing practices and a patent-pending delivery system, gemicel®, which allows for targeted ora
What does Assembly Biosciences Inc's logo look like?
Complete history of Mr Samar stock trades at Assembly Biosciences Inc、Unity Biotechnology Inc
Assembly Biosciences Inc executives and stock owners
Assembly Biosciences Inc executives and other stock owners filed with the SEC include:
-
John McHutchison,
President, Chief Executive Officer, Director -
Jacqueline Papkoff,
Senior Vice President, Chief Scientific Officer Microbiome -
Thomas Joseph Russo,
Chief Financial Officer -
Luisa Stamm,
Chief Medical Officer -
Dr. John G. McHutchison A.O., FRACP, M.D.,
CEO, Pres & Director -
Jason A. Okazaki,
Chief Operating Officer -
Dr. William E. Delaney IV, Ph.D.,
Chief Scientific Officer -
William Ringo,
Non-Executive Independent Chairman of the Board -
Myron Holubiak,
Independent Director -
Alan Lewis,
Independent Director -
Anthony Altig,
Independent Director -
Susan Mahony,
Independent Director -
Richard DiMarchi,
Independent Director -
Helen Kim,
Independent Director -
Nicole White,
Senior Vice President - Pharmaceutical Development and Manufacturing -
Gina Consylman,
Independent Director -
Jason Okazaki,
Chief Legal and Business Officer -
William Delaney,
Chief Scientific Officer - Virology -
Steven Knox,
Senior Vice President - Clinical Development -
David Houck,
Senior Vice President - Product Development and Portfolio Management -
Michele Anderson,
Chief Devel. Officer -
Dr. Tharaknath Rao,
Head of Microbiome Clinical Devel. & Sr. VP -
Dr. Richard J. Colonno,
Sr. Advisor -
Jennifer A. Troia MHROD, SHRM-SCP, SPHR,
Chief HR Officer -
Lauren Glaser,
Sr. VP of Investor Relations & Corp. Affairs -
Michael P. Samar,
CFO & Principal Accounting Officer -
Dr. Adam Zlotnick,
Co-Founder, Chief Scientific Advisor and Chair of Hbv & Virology Science Advisory Board -
Dr. Uri A. Lopatin M.D.,
Co-Founder and Clinical & Scientific Advisor -
Graham K Cooper,
See Remarks -
Mark Auerbach,
Director -
David Jonathan Barrett,
See Remarks -
Thomas E Rollins,
Chief Development Officer -
Uri A Lopatin,
Chief Medical Officer -
Michael Houghton,
-
Derek A Small,
Director -
Richard James Colonno,
EVP & CSO, Virology Ops -
Capital Fund Qualified, L.P...,
10% owner -
Lisa Johnson Pratt,
-
Anuj Gaggar,
Chief Medical Officer -
Adam Zlotnick,
10% owner -
Sciences, Inc. Gilead,
10% owner -
Michael P. Samar,
Chief Financial Officer -
Jeanette M Bjorkquist,
Principal Accounting Officer -
Alexander Schornstein,
10% owner